ANO2基因变异与新血管性AMD抗VEGF治疗反应:VIEW 1和VIEW 2的药物遗传学子研究
该药物遗传学子研究纳入VIEW 1和VIEW 2随机临床试验中同意可选药物遗传学分析的患者780例样本,进行全基因组关联分析。经Bonferroni校正和基线风险因素调整后,既往已知的AMD预后基因变异与关键预设终点均无显著关联;全基因组层面,ANO2基因(染色体12)上的一组变异与治疗1年后视力丧失≥5个字母达到显著水平(P < 5 × 10-8),其中rs2110166 SNP关联高度显著(P = 1.99 × 10-8)。
要点
- 既往已知的AMD预后候选基因均与接受治疗患者的临床终点无显著关联。
- ANO2基因簇与治疗1年后视力丧失≥5个字母显著关联(P < 5 × 10-8),rs2110166 SNP关联高度显著(P = 1.99 × 10-8)。
- ANO2 rs2110166 TT基因型携带者较基线视力稳健提高,而TC基因型携带者较基线轻度下降。
核心结论
- 既往已知的潜在预后候选基因均与接受治疗患者的临床终点无显著关联。
- 初步分析提示ANO2与视网膜功能存在关联,在至少治疗第一年内对视力可能有约一行的影响。
- 作者认为值得进一步研究ANO2在视网膜病理生理中的功能。
研究设计与样本
- VIEW 1和VIEW 2是玻璃体腔内注射阿柏西普和雷珠单抗治疗新血管性年龄相关性黄斑变性(AMD)的随机临床试验。
- 本分析为药物遗传学子研究,对同意可选药物遗传学分析的部分患者进行全基因组关联分析。
- 数据来自780例代表性样本,合并自VIEW 1和VIEW 2人群。
主要发现
- 经Bonferroni多重校正和基线风险因素统计调整后,既往已识别的AMD预后基因变异与VIEW 1和2关键预设终点的治疗反应均无显著关联。
- 全基因组层面,治疗1年或2年后视力提高≥15个早期糖尿病视网膜病变研究(ETDRS)字母的患者中未发现显著遗传关联。
- 染色体12上ANO2(编码anoctamin 2,一种光感受器细胞表达的钙激活氯通道)的一组变异与治疗1年后视力丧失≥5个字母达到显著水平(P < 5 × 10-8)。
- ANO2 rs2110166 SNP显示高度显著关联(P = 1.99 × 10-8)。
- ANO2 rs2110166 TT基因型携带者较基线视力稳健提高,而TC基因型携带者较基线轻度下降。
关键数值与推荐
- ANO2基因簇与治疗1年后视力丧失≥5个字母的关联P < 5 × 10-8。
- ANO2 rs2110166 SNP关联P = 1.99 × 10-8。
局限性
- 作者结论指出,需进一步研究ANO2在视网膜病理生理中的功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This analysis investigated potential associations between gene variants and clinical end points in the VIEW 1 and 2 randomized clinical trials of intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD). METHODS: A genome-wide association analysis was conducted in a subgroup of patients from VIEW 1 and 2 consenting to the optional pharmacogenetic analysis. RESULTS: Data were pooled from 780 samples from patients representative of the overall VIEW 1 and 2 populations. After Bonferroni correction for multiplicity and statistical adjustment for baseline risk factors, no significant associations were found between previously identified prognostic AMD gene variants and treatment response according to key prespecified VIEW 1 and 2 end points. Genome-wide, there were no significant genetic associations in patients experiencing gains of ≥15 Early Treatment of Diabetic Retinopathy Study letters after 1 or 2 years of treatment. A cluster of variants in ANO2 (encoding anoctamin 2, a calcium-activated chloride channel expressed on photoreceptor cells) on chromosome 12 reached the level of significance for loss of ≥5 letters after 1 year of treatment (P < 5 × 10-8), with the ANO2 rs2110166 SNP demonstrating highly significant association (P = 1.99 × 10-8). Carriers of the ANO2 rs2110166 TT genotype showed a robust increase in visual acuity versus baseline compared with a small decrease in those with the TC genotype. CONCLUSIONS: None of the potential prognostic candidate genes were associated with the clinical end points for treated patients. Preliminary analyses suggest an association of ANO2 with retinal function, with a potential impact on vision of approximately one line over at least the first year. Further investigation of the function of ANO2 in retinal pathophysiology is merited.
引用
- Guymer RH, Silva R, Ghadessi M, et al. ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2. Invest Ophthalmol Vis Sci. 2024. PMID: 38980270. doi:10.1167/iovs.65.8.17
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。